We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cell Block Prep Method Modified for Molecular Studies

By LabMedica International staff writers
Posted on 14 May 2018
Print article
Image: A microscopic appearance of cell blocks prepared by the HistoGel + ethanol (EtOH) method versus HistoGel-only and the EtOH-only methods. The insets in C and F illustrate excellent cytomorphologic preservation with this method (Photo courtesy of Memorial Sloan Kettering Cancer Center).
Image: A microscopic appearance of cell blocks prepared by the HistoGel + ethanol (EtOH) method versus HistoGel-only and the EtOH-only methods. The insets in C and F illustrate excellent cytomorphologic preservation with this method (Photo courtesy of Memorial Sloan Kettering Cancer Center).
Biomarker testing is currently required to guide the selection of a growing number of targeted therapies in patients with a wide range of malignancies. Combined with increasing use of immunostaining for tumor diagnosis, this has substantially increased the demand for the amount of tissue in small specimens.

Recently, next-generation sequencing platforms have entered clinical practice. These platforms afford the ability to consolidate testing of multiple genes and types of alterations into a single platform; however, some next-generation sequencing platforms require substantially larger DNA input than standard molecular methods. For cytology specimens to remain a viable diagnostic modality in the era of personalized medicine, it is crucial for those specimens to consistently provide sufficient material for diagnostic and predictive ancillary studies.

Pathologists from Memorial Sloan Kettering Cancer Center (New York, NY, USA) tested multiple modifications of the cell block preparation protocol to identify a method with the greatest cell capture using split fine-needle aspirations (FNAs) and scrapes from fresh, surgically resected tumors (ex vivo samples). Ex vivo FNAs were prepared using a 25-gauge needle, and scrapes were prepared by gently scraping the cut surface of a tumor with a surgical blade. The team developed an improved HistoGel)-based cell block preparation method. Cellularity yield with the new versus the standard method was assessed in ex vivo split samples and in consecutive clinical fine-needle aspirates processed before and after.

The scientists reported that the key modification in the new method was pretreatment of the pelleted cells with 95% ethanol before the addition of HistoGel (HistoGel + ethanol method). In addition, they optimized the melting conditions of HistoGel and added a dark, inorganic marker to the cell pellets to highlight the desired level of sectioning during microtomy. Cell blocks from ex vivo split samples showed that the HistoGel + ethanol method yielded, on average, an 8.3-fold (range, 1–20) greater cellularity compared with the standard HistoGel-only method. After the switch from the standard HistoGel method to the modified method in their clinical practice, sufficiency of positive fine-needle aspirates for some molecular studies increased from 72% to 97%.

The authors concluded that a modification of the HistoGel-based cell block preparation method that leads to substantial improvement in cell recovery from FNA needle rinses compared with the standard HistoGel method. They showed the validation of this method both in ex vivo split samples and in routine clinical FNAs before and after the implementation of the new method in their laboratory. This protocol is simple and readily adoptable and leads to substantially increased sufficiency of FNA samples for molecular testing. The study was published in the April 2018 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Memorial Sloan Kettering Cancer Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.